CROI 2025

CROI 2025
March 09-12, 2025
San Francisco

Conference on Retroviruses and Opportunistic Infections.

Explore more information for Gilead COVID-19 therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (15)

    Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay

    • Author(s): Kiweewa, FM
    • descovy-for-prep
    • HIV / AIDS
    • Oral

    T-Cell Responses Induced By GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV

    • Author(s): Huang, S
    • gs-1966
    • HIV / AIDS
    • Oral

    Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1

    • Author(s): Gill, K
    • sunlenca
    • HIV / AIDS
    • Oral

    Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir

    • Author(s): Jogiraju, V
    • sunlenca
    • HIV / AIDS
    • Oral

    Bictegravir + Lenacapavir: Baseline and Week 48 Resistance in ARTISTRY-1 Phase 2

    • Author(s): Margot, N
    • sunlenca
    • HIV / AIDS
    • Poster

    Weight Change on F/TAF vs Placebo: Using Common F/TDF Groups to Bridge Data Across Clinical Trials

    • Author(s): Glidden, D
    • descovy
    • HIV / AIDS
    • Poster

    Evaluation Of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With Hiv-1 During ATI

    • Author(s): Dong, K
    • vestalimod-(gs-9620)
    • HIV / AIDS
    • Oral

    Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 26 Primary Outcome

    • Author(s):
    • sunlenca
    • HIV / AIDS
    • Oral

    Machine Learning Identifies Predictors of Delayed or No Remdesivir Use in Hospitalized COVID-19 Patients

    • Author(s): Ferreira, A
    • veklury
    • COVID-19
    • Poster

    Patterns of Remdesivir Initiation in Immunocompromised Patients Hospitalized With COVID-19

    • Author(s): Berry, M
    • veklury
    • COVID-19
    • Poster

    Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks

    • Author(s): VanderVeen, L
    • sunlenca
    • HIV / AIDS
    • Poster

    Week 24 Outcomes Of F/TAF Plus Cobicistat-Boosted Protease Inhibitors in Children ≥2 Y and ≥14 Kg

    • Author(s): Mujuru, H
    • descovy
    • HIV / AIDS
    • Poster

    Renal Outcomes In People With HIV-1 And Renal Impairment Treated With B/F/TAF in Randomized Trials

    • Author(s): Post, F
    • biktarvy
    • HIV / AIDS
    • Poster

    HIV-1 Resistance Analysis of Treatment-Naïve People With HIV And HBV Receiving B/F/TAF Or DTG+F/TDF

    • Author(s): D'Antoni, M
    • biktarvy
    • HIV / AIDS
    • Poster

    ALLIANCE OLE: Switch To B/F/TAF In People With Both HIV-1 and HBV

    • Author(s): Avihingsanon, A
    • biktarvy
    • HIV / AIDS
    • Poster